Immunovant shifts gears, favouring IMVT-1402 over batoclimab in FcRn race
30 May 2024
Immunovant is realigning its clinical development plans, prioritising the next-generation FcRn inhibitorFcRn inhibitor IMVT-1402 as its lead asset over previously touted batoclimab. This decision has led to a postponement of clinical readouts for batoclimab, as the company doubles down on the perceived potential of IMVT-1402 across multiple autoantibody-driven indications.
In a corporate update, Immunovant said it is looking to start four to five potentially registrational studies for IMVT-1402 by the end of March 2025, spanning therapeutic areas such as endocrinology and neurology. By the end of 2026, it hopes to raise that number to a total of 10 indications.
"We are very excited about the immunology market evolution that we believe positions the anti-FcRn mechanism to be the leading therapeutic class across a broad range of autoantibody-driven indications," said CEO Pete Salzmann. "Within the class, we see tremendous opportunity for IMVT-1402, which we believe has a combination of potentially best-in-class features not seen with any other FcRn inhibitorFcRn inhibitor."
More to follow.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.